A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML

Disease Area: Leukemia, Acute Myeloid (AML)
Investigator: Colleen Delaney
Institution: Nohla Therapeutics Inc
CIRM Grant: CLIN2-09574
Award Value: $6,922,109
Trial Sponsor: Nohla Therapeutics Inc
Trial Stage: Phase 2
Trial Status: Recruiting
Targeted Enrollment: 220
ClinicalTrials.gov ID: NCT03301597

Details:
Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.

Design:
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.

Goal:
Evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.

News about this clinical trial:
Nohla Therapeutics Awarded $6.9 Million Grant From The California Institute for Regenerative Medicine
Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML

Source URL: https://www.cirm.ca.gov/clinical-trial/phase-2-open-label-multi-center-randomized-controlled-optimal-dose-finding-study-0